Related Experiment Videos
Molecular genetic analysis of TGF-beta1 in ovarian neoplasia
M R Cardillo1, E Yap, G Castagna
1Histopatology Unit, University La Sapienza of Rome, Italy.
Abstract:
Malignant ovarian tumours have been associated with a loss of autocrine growth inhibition by transforming growth factor-beta. This study aimed to detect abnormalities in the gene structure, expression and localization of TGF-beta1, in paraffin-embedded samples from 31 ovarian neoplasias (21 malignant, 5 borderline and 5 benign). Gene mutations in the region coding for the active protein were detected by PCR-SSCP analysis of exons 5, 6 and 7. mRNA expression and localization was studied by nonisotopic in situ hybridization (NISH) using cDNA probes generated by the reverse transcriptase polymerase chain reaction (RT-PCR), and immunohistochemistry, using antibodies against both intracellular and extracellular (matrix-associated) forms of TGF-beta1. Four mutations were found: one in exon 6 (serous adenocarcinoma), one in exon 7 (Mullerian tumor), and two in exons 5 and 6 from a serous cystoadenoma. TGF-beta1 mRNA was expressed in 87% and proteins in 90% of ovarian tumours. Most tumours expressing large amounts of TGF-beta1 mRNA, also contained a large number of protein binding sites. In malignant tumors, TGF beta1 was more strongly expressed in high-grade ovarian carcinomas with a cystic-papillary pattern than in tumours with a solid growth pattern. Normal ovarian tissue (follicles, granulosa cells) adjacent to tumor showed weak epithelial labeling and staining. Gene mutation did not correlate with histological type of tumor, mRNA or protein expression. TGF-beta1 mutation and abnormalities in its expression seem to occur in benign and malignant ovarian tumors, and could be involved in their pathogenesis. TGF beta1 gene mutations may act in multistage ovarian neoplasia, by reducing epithelial cell responsiveness to TGF-beta1 negative growth control.
Insights
Transforming growth factor-beta1 (TGF-beta1) gene mutations and expression abnormalities are observed in ovarian tumors, potentially contributing to their development by disrupting growth inhibition.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Malignant ovarian tumors often exhibit a loss of autocrine growth inhibition mediated by transforming growth factor-beta (TGF-beta).
- Investigating TGF-beta1 in ovarian neoplasia is crucial for understanding tumor pathogenesis.
Purpose of the Study:
- To detect abnormalities in the gene structure, expression, and localization of TGF-beta1 in ovarian tumors.
- To correlate these findings with tumor type and grade.
Main Methods:
- Analysis of TGF-beta1 gene mutations in exons 5, 6, and 7 using PCR-SSCP.
- Assessment of mRNA expression and protein localization via nonisotopic in situ hybridization (NISH) and immunohistochemistry.
Main Results:
- Four TGF-beta1 gene mutations were identified across different ovarian tumor types.
- TGF-beta1 mRNA and protein were expressed in the majority of ovarian tumors (87% and 90%, respectively).
- Higher TGF-beta1 expression was noted in high-grade, cystic-papillary ovarian carcinomas compared to solid tumors.
Conclusions:
- TGF-beta1 gene mutations and expression abnormalities occur in both benign and malignant ovarian tumors.
- These alterations may play a role in ovarian neoplasia development by impairing cellular response to TGF-beta1's growth-inhibitory signals.